In:
Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 29, No. 8 ( 2022-03), p. 1436-1458
Abstract:
Triple-negative breast cancer (TNBC) is a highly resistant, lethal, and metastatic
sub-division of breast carcinoma, characterized by the deficiency of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
In women, TNBC shows a higher aggressive behavior with poor patient prognosis and a higher recurrence rate during reproductive age. TNBC is defined by the presence of epithelial-
to-mesenchymal-transition (EMT), which shows a significant role in cancer progression. At the epigenetic level, TNBC is characterized by epigenetic signatures, such as
DNA methylation, histone remodeling, and a host of miRNA, MiR-193, LncRNA, HIF- 2α, eEF2K, LIN9/NEK2, IMP3, LISCH7/TGF-β1, GD3s, KLK12, mediated regulation.
These modifications either are silenced or activate the necessary genes that are prevalent in TNBC. The review is based on epigenetic mediated mechanistic changes in TNBC.
Furthermore, Thymoquinone (TQ), Regorafenib, Fangjihuangqi decoction, Saikosaponin A, and Huaier, etc., are potent antitumor natural compounds extensively reported in the
literature. Further, the review emphasizes the role of these natural compounds in TNBC and their possible epigenetic targets, which can be utilized as a potential therapeutic strategy
in the treatment of TNBC.
Type of Medium:
Online Resource
ISSN:
0929-8673
DOI:
10.2174/0929867328666210707165530
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
detail.hit.zdb_id:
1319315-6
SSG:
15,3
Permalink